Accessibility Menu
BioLineRx logo

BioLineRx(NASDAQ) BLRX

Current Price$2.86
Market Cap$12.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-98%
1 Year-37%
1 Month-16%
BioLineRx last closing stock price
MetricPriceDate
Last closeUSD 2.822026-07-24
BioLineRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.76%USD 2.902026-07-17
1 month-16.32%USD 3.372026-06-24
3 month+24.23%USD 2.272026-04-24
Year to date+1.81%USD 2.772025-12-31
1 year-37.47%USD 4.512025-07-24
3 year-95.27%USD 59.602023-07-25
5 year-97.85%USD 131.202021-07-23
Since inception-99.92%USD 3,354.002011-07-25

BioLineRx Financials at a Glance

Market Cap

$12.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.40M

Net Income (TTM)

-$8.89M

EPS (TTM)

-$2.14

P/E Ratio

-1.32

Dividend

$0.00

Beta (Volatility)

0.80 (Low)

Price

$2.86

Volume

158

Open

$2.86

Previous Close

$2.86

Daily Range

$2.86 - $2.86

52-Week Range

$2.15 - $4.56

Estimated Earnings Date

Aug 13, 2026

BLRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioLineRx

BioLineRx Ltd. is an Israeli biopharmaceutical company focused on developing innovative therapies primarily in oncology. Established in 2003, the company is advancing its clinical-stage pipeline, which includes promising candidates for various cancers and other serious conditions.

Products and Services
  • Motixafortide: A peptide in Phase 2 studies for metastatic pancreatic adenocarcinoma
  • AGI-134: An immuno-oncology agent in Phase 1/2a trials for solid tumors
  • BL-5010: A proprietary device for non-surgical removal of skin lesions
Growth Outlook
  • Motixafortide has completed pivotal Phase 3 trials, indicating strong potential for market entry
  • Strategic collaborations with MSD and MD Anderson enhance research capabilities and market reach
  • Ongoing studies for Motixafortide in acute respiratory distress syndrome may open new therapeutic avenues
Financial Highlights
  • Recent quarterly revenue of $477,000 reflects ongoing clinical development efforts
  • Cash and short-term investments total approximately $17.35 million, providing operational runway
  • Net income for Q1 2026 was a loss of $2.59 million, consistent with R&D investments
BioLineRx Ltd. is positioned in the biotechnology sector with a focus on oncology, leveraging its innovative pipeline to address unmet medical needs. The company's lead product, Motixafortide, has shown promise in clinical trials, particularly for pancreatic cancer, which is a significant area of focus given the high mortality rates associated with this disease. The strategic partnerships with established entities like MSD and MD Anderson Cancer Center not only bolster BioLineRx's research capabilities but also enhance its credibility in the competitive biopharmaceutical landscape. Financially, the company is navigating through a phase of substantial investment in research and development, which is reflected in its recent quarterly losses. However, the available cash reserves and ongoing clinical trials suggest a commitment to advancing its product pipeline. Investors may find BioLineRx's focus on innovative therapies and strategic collaborations appealing as the company seeks to make significant strides in the oncology market.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

24

CEO

Philip Adam Serlin, MBA, CPA

Website

www.biolinerx.com

Headquarters

Hevel Modi'in, HM 7177871, IL

BLRX Financials

Key Financial Metrics (TTM)

Gross Margin

74.67%

Operating Margin

-780.21%

Net Income Margin

-633.83%

Return on Equity

-47.86%

Return on Capital

-36.58%

Return on Assets

-22.97%

Earnings Yield

-75.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.37M

Volume

158

Avg. Volume

53.05K

Financials (TTM)

Gross Profit

$1.05M

Operating Income

-$10.92M

EBITDA

-$8.20M

Operating Cash Flow

-$7.79M

Capital Expenditure

-$31.20K

Free Cash Flow

-$7.82M

Cash & ST Invst.

$17.35M

Total Debt

$9.07M

BioLineRx Performance Analysis

BioLineRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 4,787,631N/A
20242024-12-31USD 29,077,355507.3%
20252025-12-31USD 1,189,361-95.9%
BioLineRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3019.2%
Q32025-09-3040.5%
Q42025-12-31-54.3%
Q12026-03-31144.4%
BioLineRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -19.27-21.4%
20232023-12-31USD -37.6595.4%
20242024-12-31USD -4.64-87.7%
20252025-12-31USD -0.29-93.7%
BioLineRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-138.7%
Q32025-09-3077.9%
Q42025-12-31-44.9%
Q12026-03-31-81.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$477.00K

+87.1%

Gross Profit

$382.00K

+72.9%

Gross Margin

80.08%

N/A

Market Cap

$12.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$615.93K

N/A

Employees

20

N/A

Net Income

-$2.58M

-150.3%

EBITDA

-$2.25M

-139.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$17.35M

-34.2%

Total Debt

$9.07M

-34.0%

Accounts Receivable

$1.89M

-1.6%

Inventory

$2.16M

-34.9%

Long Term Debt

$4.34M

-49.7%

Short Term Debt

$4.73M

-7.7%

Return on Assets

-22.97%

N/A

Return on Invested Capital

-43.58%

N/A

Free Cash Flow

-$2.29M

+11.8%

Operating Cash Flow

-$2.28M

+12.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MBRXMoleculin Biotech, Inc.
$2.12+1.92%
ICUSeaStar Medical Holding Corporation
$3.75+0.27%
LNAILunai Bioworks Inc.
$2.33+0.43%
AIMDAinos, Inc.
$1.40-7.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Questions About BLRX

What is the current price of BioLineRx?

BioLineRx is trading at $2.86 per share.

What is the 52-week range for BioLineRx?

Over the past 52 weeks, BioLineRx has traded between $2.15 and $4.56.

How much debt does BioLineRx have?

As of the most recent reporting period, BioLineRx reported total debt of $9.07M.

How much cash does BioLineRx have on hand?

BioLineRx reported $2.50M in cash and cash equivalents in its most recent financial results.

What is BioLineRx’s dividend yield?

BioLineRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services